/>

Talks on with Pfizer, J&J, Moderna for possible local manufacturing: Shringla

MEA says it is making ‘all efforts’ to increase vaccine supplies, particularly from U.S.

Updated - June 03, 2021 07:11 pm IST - NEW DELHI

Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture. File

Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture. File

India was in talks to allow major foreign vaccine manufacturers to carry out “local manufacturing”, said Foreign Secretary Harsh Vardhan Shringla on Thursday, as the Ministry of External Affairs (MEA) asserted it was making “all efforts” to increase vaccine supplies, particularly from the U.S.

Also read: India eases norms for clearing foreign-made COVID-19 vaccines

Addressing the WHO’s South-East Asia Regional Health Partners’ Forum, Mr. Shringla stated that India was fighting an “exceptionally severe second wave”of the pandemic.

“We are also part of the discussions with major vaccine manufacturers like Pfizer , Johnson & Johnson and Moderna about sourcing and possible local manufacturing of their vaccines in India. We have also helped expedite the introduction of Sputnik-V vaccines,” he said, elaborating on the MEA’s role in securing vaccines.

Also read: Pace of vaccination suggests complete immunisation unlikely by year end

In an order on February 5 last, U.S. President Joe Biden had invoked the Defence Production Act for vaccine components, putting a squeeze on India’s vaccine manufacturing.

India had been demanding easier access to raw materials necessary for vaccine production.

Mr. Shringla said MEA’s representatives have been working to “ease regulatory disruptions to these supply chains”.

Jaishankar’s U.S. visit

MEA spokesperson Arindam Bagchi, replying to questions on the outcome of Mr. Jaishankar’s week-long U.S. visit, said, “We are also engaged with the U.S. administration to ensure that necessary components and raw materials for vaccine production in India are readily available. This issue was taken up most recently during External Affairs Minister [Jaishankar]’s visit to the U.S”.

India was also awaiting the U.S. allocations from its surplus stockpile of 80 million Astra Zeneca vaccines, he added.

In his address to the WHO, Mr. Shringla said India would create “global scale capacities” necessary to fight the pandemic. “A number of serious global conversations are underway on this in platforms such as th G7, th G20, QUAD, BRICS, the United Nations and the WTO itself,” he noted.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.